[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335126":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":44,"responsibleParty":100,"collaborators":102,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":111,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":26,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":133,"whyStopped":26,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"University of Zurich","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sevoflurane Sedation","EXPERIMENTAL","Patients randomized into experimental group will be treated with sevoflurane during 4 hours",[13],"Drug: Sevoflurane",{"label":15,"type":16,"description":17,"interventionNames":18},"Propofol Sedation","ACTIVE_COMPARATOR","Patients randomized into Control Group will get continued intravenous sedation with propofol",[19],"Drug: Control Group",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sevoflurane","Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Control Group","Included patients randomized in control group, intravenouse sedation is continued with propofol",[15],[32],"Propofol",[34],{"name":35,"affiliation":5,"role":36},"Martin Schlaepfer, PD","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":26,"email":41},"CONTACT","+41 44 255 4690","martin.schlaepfer@usz.ch",{"name":43,"role":39,"phone":40,"phoneExt":26,"email":41},"Martin Schläpfer, PD",[45,62,76,90],{"facility":46,"status":26,"city":47,"state":26,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Kantonasspital Münsterlingen","Münsterlingen","8596","Switzerland","CH",{"type":52,"coordinates":53},"Point",[54,55],9.23271,47.63197,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":26,"email":61},"Thomas Neff, PD Dr. med.","071 686 2108","thomas.neff@sec.stgag.ch",{"facility":63,"status":26,"city":64,"state":26,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Stadtspital Triemli","Zurich","8063",{"type":52,"coordinates":67},[68,69],8.55,47.36667,{"lat":69,"lon":68},[72],{"name":73,"role":39,"phone":74,"phoneExt":26,"email":75},"Patricia Fodor, KD Dr. med.","+41444165202","patricia.fodor@triemli.zuerich.ch",{"facility":77,"status":26,"city":64,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":80,"contacts":81},"University Hospital of Zurich",{"type":52,"coordinates":79},[68,69],{"lat":69,"lon":68},[82,85,88],{"name":83,"role":39,"phone":84,"phoneExt":26,"email":41},"Martin Schlaepfer, PD Dr med","+41442551111",{"name":86,"role":39,"phone":26,"phoneExt":26,"email":87},"Beatrice Beck Schimmer, Prof Dr med","beatrice.beck@usz.ch",{"name":89,"role":36,"phone":26,"phoneExt":26,"email":26},"Marco Maggiorini, Prof Dr med",{"facility":91,"status":26,"city":64,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"Waidspital Zürich",{"type":52,"coordinates":93},[68,69],{"lat":69,"lon":68},[96],{"name":97,"role":39,"phone":98,"phoneExt":26,"email":99},"Christian Giambarba, Dr. med.","+41443662021","christian.giambarba@waid.zuerich.ch",{"type":101,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[103,105,107],{"name":104,"class":6},"Kantonsspital Münsterlingen",{"name":106,"class":6},"Triemli Hospital",{"name":108,"class":6},"Waid City Hospital, Zurich","100335126","phase-2-sevoflurane-sedation-in-patients-with-septic-shock-100335126",false,"NCT03643367","Sevoflurane Sedation in Patients With Septic Shock","Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock","SSiS","Inclusion Criteria:\n\n* Male and female patients, age 18 to 80 years\n* Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury (mmHg), and serum lactate \\>2mmol\u002Fl even with fluid application)\n* Treatment of septic shock on ICU with vasopressors not longer than 12 hours\n* Sedation and mechanical ventilation on ICU\n* Female patients of childbearing potential with negative pregnancy test\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* Previous surgery and\u002For anesthesia (within last 7 days)\n* Application of nitric oxide (NO)\n* Suspected or known intolerance by history to volatile anesthetics (malignant hyperthermia)\n* Immunosuppressive agents\n* Systemic corticosteroids in the phase before hospitalization (\\> 10mg\u002Fd prednisone)\n* Significant concomitant disease (acute cerebral vascular event, acute coronary syndrome, decompensated heart failure, acute pulmonary edema, major cardiac arrhythmia, seizure, burn, chronic kidney disease, end stage liver failure, neuromuscular disease)\n* AIDS\n* Autoimmune disease\n* Organ transplant\n* Subject with active malignancy receiving\n* chemotherapy or radiation treatment within last 60 days\n* Hepatitis B\u002FC virus infection\n* Anti-tumor necrosis factor (TNF) therapy\n* Pregnancy and\u002For Breast feeding\n* Use of cytokine absorber\n* Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion","ALL","18 Years","80 Years",{"count":121,"type":122},153,"ESTIMATED","INTERVENTIONAL",[125],"PHASE2","Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.\n\nPatients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.",[128],"Shock, Septic",[130,131,132],"Sepsis","Septic Shock","Sevoflurane Conditioning","NOT_YET_RECRUITING","2025-03-26",{"date":136,"type":137},"2025-04-01","ACTUAL",{"date":139,"type":122},"2026-01",{"date":141,"type":122},"2027-11",{"name":5,"class":6},4]